Literature DB >> 35575750

A Systematic Review and Meta-Analysis of the Association Between Polycystic Ovary Syndrome and Coronary Artery Calcification.

Olatokunbo Osibogun1, Oluseye Ogunmoroti2,3, Olamide B Kolade4, Allison G Hays3, Victor Okunrintemi5, Anum S Minhas2,3, Martha Gulati6, Erin D Michos2,3.   

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common endocrine pathology affecting women of reproductive age characterized by chronic anovulation, hyperandrogenism, and polycystic ovaries. Coronary artery calcification (CAC) is a marker of subclinical atherosclerosis and prognostic of cardiovascular disease (CVD) risk. Some studies have shown that women with PCOS have a greater risk of CAC; however, a few others report contrary findings. The objective of this study is to examine and quantify the association between PCOS and CAC. Materials and
Methods: We searched EMBASE, Google Scholar, PubMed, and Web of Science from inception to November 2021 to identify studies that provided information on PCOS and CAC. We used a random-effects model to aggregate the odds ratios (ORs) for CAC (score >0) among women with PCOS compared with controls adjusted for sociodemographic characteristics and CVD risk factors.
Results: From the 36 articles reviewed, 3 prospective cohort and 4 cross-sectional studies met the inclusion criteria with a total of 2341 participants. Six studies used CAC > 0 as an outcome and were included in the pooled analysis. Using the Hartung-Knapp-Sidik-Jonkman method, the pooled adjusted ORs for the associations between PCOS and the presence of CAC were 2.48 (95% confidence interval: 2.11-2.84) with no significant heterogeneity (I2 = 0.10%, p = 0.97) for the cohort studies and 1.88 (0.71-3.06) with no significant heterogeneity (I2 = 13.95%, p = 0.87) for the cross-sectional studies.
Conclusion: In pooled analyses, women with PCOS had approximately twofold greater odds of having CAC compared with women without PCOS. However, additional prospective studies will be needed to further understand the relationship between PCOS and CAC.

Entities:  

Keywords:  atherosclerosis; cardiovascular disease; coronary artery calcification; polycystic ovary syndrome; risk factors

Mesh:

Year:  2022        PMID: 35575750      PMCID: PMC9360175          DOI: 10.1089/jwh.2021.0608

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   3.017


  39 in total

1.  Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.

Authors:  Joan C Lo; Seth L Feigenbaum; Jingrong Yang; Alice R Pressman; Joe V Selby; Alan S Go
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

Review 2.  Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.

Authors:  Olatokunbo Osibogun; Oluseye Ogunmoroti; Erin D Michos
Journal:  Trends Cardiovasc Med       Date:  2019-09-04       Impact factor: 6.677

3.  Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.

Authors:  L Gao; F-L Zhao; S-C Li
Journal:  Exp Clin Endocrinol Diabetes       Date:  2012-05-25       Impact factor: 2.949

4.  Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study.

Authors:  Clare Oliver-Williams; Ditte Vassard; Anja Pinborg; Lone Schmidt
Journal:  Eur J Prev Cardiol       Date:  2020-08-02       Impact factor: 7.804

5.  Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease, and Stroke.

Authors:  Tiantian Zhu; Jinrui Cui; Mark O Goodarzi
Journal:  Diabetes       Date:  2020-11-06       Impact factor: 9.461

6.  Complement protein C3 and coronary artery calcium in middle-aged women with polycystic ovary syndrome and controls.

Authors:  Michelle L Snyder; Kelly J Shields; Mary T Korytkowski; Kim Sutton-Tyrrell; Evelyn O Talbott
Journal:  Gynecol Endocrinol       Date:  2014-03-05       Impact factor: 2.260

7.  Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention.

Authors:  Erin D Michos; Michael J Blaha; Roger S Blumenthal
Journal:  Mayo Clin Proc       Date:  2017-11-03       Impact factor: 7.616

Review 8.  A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.

Authors:  Mitra Niafar; Leili Pourafkari; Jahan Porhomayon; Nader Nader
Journal:  Arch Gynecol Obstet       Date:  2015-12-10       Impact factor: 2.344

9.  Hypertension in Young Women: Implications of the Polycystic Ovary Syndrome and Opportunities for Prevention and Further Research.

Authors:  Lara C Kovell; Stephen P Juraschek; Erin D Michos
Journal:  J Clin Endocrinol Metab       Date:  2021-08-18       Impact factor: 6.134

Review 10.  Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention.

Authors:  Petal Elder; Garima Sharma; Martha Gulati; Erin D Michos
Journal:  Am J Prev Cardiol       Date:  2020-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.